FDA Recalls Over 11,000 Bottles of Blood Pressure Drug Due to Cholesterol Medication Cross-Contamination
核心洞察
Glenmark Pharmaceuticals has recalled more than 11,000 bottles of bisoprolol fumarate and hydrochlorothiazide tablets (brand name Ziac) after testing revealed cross-contamination with ezetimibe, a cholesterol medication.
The FDA classified this as a Class III recall, indicating the contamination is not likely to cause adverse health consequences, though the products are being removed from distribution as a precautionary measure.
The recall affects multiple dosage strengths and bottle sizes with expiration dates ranging from November 2025 through May 2026, manufactured at Glenmark's facility in Madhya Pradesh, India.
Glenmark Pharmaceuticals Inc. has initiated a nationwide recall of more than 11,000 bottles of a widely prescribed blood pressure medication after quality control testing revealed unexpected cross-contamination with a cholesterol drug. The recall, announced by the FDA on December 1, affects bisoprolol fumarate and hydrochlorothiazide tablets sold under the brand name Ziac.
Contamination Discovery
Testing of reserve samples showed the presence of traces of ezetimibe, a cholesterol medication also manufactured by Glenmark, according to the FDA recall report. The contamination was discovered during routine quality-control checks at the company's New Jersey facility, which has U.S. headquarters in Elmwood Park.
Both the blood pressure medication and the cholesterol drug are produced by Glenmark Pharmaceuticals, with the recalled tablets manufactured in Madhya Pradesh, India. The cross-contamination represents what regulators described as an "unacceptable mix-up involving a drug meant for a completely different condition."
Recall Classification and Risk Assessment
The FDA has classified this recall as Class III, the lowest risk tier, indicating that "use of or exposure to a violative product is not likely to cause adverse health consequences." Despite the low-risk designation, the agency ordered the product removed from distribution as a precautionary measure and urged pharmacies and healthcare providers to check their inventory.
Affected Products and Lot Information
The recall encompasses multiple dosage strengths and bottle sizes:
- 30-tablet bottles (NDC-68462-878-30): Lot 17232401, expiring November 2025
- 100-tablet bottles (NDC-68462-878-01): Lot 17232401, expiring November 2025
- 500-tablet bottles (NDC-68462-878-05): Lots 17232401 (expiring November 2025) and 17240974 (expiring May 2026)
The affected products include both 2.5-milligram and 6.25-milligram dosage strengths, with expiration dates ranging from November 2025 through May 2026.
Medication Function and Patient Impact
Bisoprolol fumarate and hydrochlorothiazide work as a combination therapy for hypertension management. According to medical sources, bisoprolol blocks beta-1 receptors in the heart, allowing normal heart rhythm regulation, while hydrochlorothiazide increases urination to remove sodium and water from the body and helps relax blood vessels. Together, this combination helps lower blood pressure and reduces the risk of heart attacks and strokes.
Patient and Provider Guidance
Patients currently taking the medication have been advised to continue using it unless directed otherwise by their doctor, given the low-risk nature of the contamination. However, affected individuals are recommended to check their medication's lot number, contact their pharmacist and prescriber, and properly dispose of any recalled medication.
The recall underscores ongoing regulatory oversight of pharmaceutical manufacturing facilities and highlights how quality-control lapses can impact the drug supply chain, even when the health risks are minimal.